Letter

Lipid lowering drugs in diabetes: Lipid lowering has ophthalmic benefits

BMJ 2006; 332 doi: 10.1136/bmj.332.7552.1272-b (Published 25 May 2006)
Cite this as: BMJ 2006;332:1272.3

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Hiten G Sheth, specialist registrar (drhitensheth@yahoo.co.uk),
  2. Sher Aslam, senior house officer,
  3. Nigel Davies, consultant
  1. Department of Ophthalmology, Chelsea and Westminster Hospital, London SW10 9NH
  2. Department of Ophthalmology, Chelsea and Westminster Hospital, London SW10 9NH

    EDITOR—Lipid lowering treatment in diabetes has ophthalmic benefits.1 Diabetic maculopathy is a common cause of loss of sight in diabetic patients and is characterised by retinal oedema and lipid exudates. The use of atorvastatin in diabetic maculopathy has recently been shown in a randomised controlled trial to decrease visible lipid exudates and …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular